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Abstract
Objectives: To investigate homoarginine and asymmetric 
dimethylarginine (ADMA) in controls compared to chil-
dren with type 1 diabetes (T1D) and if homoarginine and 
ADMA are affected by atorvastatin.
Methods: Homoarginine and ADMA levels of 28 T1D 
patients were compared to levels of 41 controls. In T1D 
patients, homoarginine and ADMA were determined at 
baseline, 1 year, and 2 years at daily 10 mg atorvastatin or 
placebo within a double-blind study.
Results: At baseline, both homoarginine and ADMA 
were lower (p < 0.001) in T1D patients compared to con-
trols. In T1D patients, homoarginine and ADMA were not 
influenced by atorvastatin. Inverse correlations between 
homoarginine and HbA1c (p < 0.001) and between ADMA 
and systolic blood pressure (p = 0.005) and pulse pressure 
(p = 0.003) were shown.
Conclusions: Homoarginine and ADMA levels are 
decreased and associated with cardiovascular risk fac-
tors in children with T1D without being affected by 
atorvastatin.
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Introduction
L-homoarginine (HoArg) is an amino acid supposed to be 
formed by enzymatically transamination of L-lysine using 
L-arginine:glycine-amidinotransferase (1, 2). Because 
HoArg shows structural similarity to L-arginine, it can 
serve as a substrate or act as an inhibitor for nitric oxide 
(NO) synthesis thus increasing or decreasing NO produc-
tion in the endothelium (3, 4). In adults with cardiovascu-
lar disease or type 2 diabetes, low HoArg has been shown 
to be associated with cardiovascular morbidity (5, 6) In 
children and adolescents with type 1 diabetes (T1D) who 
are known to be at risk for developing premature ath-
erosclerosis (7, 8), data on HoArg plasma concentrations 
are not available in the literature. Asymmetric dimethy-
larginine (ADMA) is an endogenous form of the amino 
acid arginine and exhibits potent inhibitory activities on 
endothelial nitric oxide synthases (eNOS) (9). Studies 
have shown that plasma ADMA can serve as a risk marker 
for endothelial dysfunction and cardiovascular disease 
(10, 11), but inconsistent data exist regarding the role of 
ADMA in patients with T1D (12, 13). In terms of medical 
treatment, statin therapy has shown contradictory effects 
on ADMA levels in adult patients with vascular disease 
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(14, 15), but therapy data as to how HoArg and ADMA 
are affected by statins in children with T1D are currently 
not available. The present article is based on a 2-year, 
double-blind, placebo-controlled study with atorvastatin 
investigating associations of HoArg and ADMA with dia-
betes-related and cardiovascular risk factors in children 
with T1D.
Materials and methods
This investigation was conducted as part of the clinical trial entitled 
Vasoprotection by Atorvastatin in Children and Adolescents with 
Type 1 Diabetes, a 2-year pilot study (ATV-D-03-005G). The protocol 
was approved by the Ethics Committee at the Albert-Ludwigs-Univer-
sity of Freiburg (registration number: 243/03; German Clinical Trials 
Register: DRKS00000297, Registry URL: http://www.germanctr.de), 
and all participants or their parents signed an informed consent.
Study and participants
The study was a randomized, double-blind, placebo-controlled clini-
cal trial. From 2005 to 2010, protocol-specified enrolment, monitor-
ing, and treatment administration of study participants were carried 
out. Children with T1D (n = 28) were randomly allocated to receive 
either 10  mg atorvastatin (n = 18) or placebo (n = 10). There were six 
dropouts due to one fatal traffic accident and five cases of non-
compliance because of poor glycemic control with HbA1c  > 9.5% 
measured twice within a period of 4 weeks, inadequate intake of the 
study medication, or failure to attend the study visits. For ethical 
reasons and to avoid unnecessary use of atorvastatin therapy, only 
diabetic children with carotid intima-media thickness values (A. 
Schmidt-Trucksäss) above the 75th percentile were included (7). T1D 
was diagnosed according to the American Diabetes Association (16). 
For comparison, 41 healthy age- and sex-matched controls were col-
lected during a systematic health preventative check-up at a practice 
for pediatrics and adolescent medicine. None of the controls received 
any medical therapy. In children with T1D, only specific diabetic 
treatment and study medication were allowed. Further characteris-
tics of controls and patients are summarized in Table 1.
Clinical and laboratory examinations
Standard deviation scores for body mass index (kg/m2) were calcu-
lated using corresponding normative data for German children (17). 
Blood pressure was measured as the average of three measurements 
using the Dinamap pediatric monitor (Critikon, Tampa, FL, USA) with 
the appropriate cuff size for the upper arm. Brachial pulse pressure 
was calculated as the difference between systolic and diastolic blood 
pressure. Albumin in urine was determined in children with T1D on 
first morning urine samples (BN ProSpec system, Siemens Healthcare 
Diagnostics, Marburg, Germany) taken at the end of the follow-up 
period. Serum creatinine was measured (Roche Cobas System 8000, 
Module c702, Roche Diagnostics GmbH, Mannheim, Germany) in 
children with T1D at baseline and at the end of the follow-up period. 
Evaluation and monitoring of glycemic status was achieved by the 
determination of HbA1c which was standardized according to the 
Diabetes Control and Complications Trial (DCCT) reference range of 
4.05–6.05% (18).
Blood samples were taken after an overnight fast for arginine, 
HoArg, and ADMA and analyzed using stable isotope dilution tech-
niques and liquid chromatography-tandem mass spectrometry (LC-
20A Shimadzu prominence, Duisburg, Germany; AB Sciex 4000 
QTRAP, Darmstadt, Germany). Blood was placed in prechilled hep-
arinized tubes and immediately spun down at 4°C. The plasma was 
deproteinized using perchloric acid (2:1) and spun down, after which 
the supernatant was transferred and stored at –80°C until analysis. 
Separation was done by liquid chromatography on a 150-mm × 3-mm 
Table 1 Baseline characteristics of children and adolescents with type 1 diabetes compared to healthy controls supplemented by plasma 
levels of arginine, ADMA, and homoarginine.
Parameters    Participants
  
p-Valuea
Type 1 diabetes
(n = 28, 27% female)
   Controls
(n = 41, 34% female)
Age, years   14.5 (13.7–15.0)  14.0 (13.5–14.0)  NS
HbA1c, %   8.3 (7.8–8.7)  –  –
Diabetes duration, years  5.5 (4.7–7.6)  –  –
Insulin, IU/kg/day   0.83 (0.73–0.96)  –  –
BMI, kg/m2   22.9 (20.3–25.3)  20.0 (19.1–21.1)  NS
BMI-SDS   0.79 (–0.04–1.51)  0.32 (–0.16–0.5)  NS
SBP, mmHg   121 (115–125)  115 (112–118)  0.015
DBP, mmHg   70 (67–73)  70 (66–71)  NS
Pulse pressure, mmHg   51 (46–55)  45 (43–48)  NS
Arginine, μmol/L   129.4 (121.1–149.0)  138.2 (128.9–150.2)  NS
ADMA, nmol/L   399.7 (357.4–478.9)  1059.5 (996.0–1179.8)    < 0.001
Homoarginine, μmol/L   0.900 (0.899–1.053)  1.420 (1.360–1.886)   < 0.001
Data are medians (95% CI); BMI-SDS, body mass index-standard deviation score; SBP, systolic blood pressure; DBP, diastolic blood pres-
sure; ADMA, asymmetric dimethylarginine; aMann-Whitney U test; NS, not significant.
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silica column with an isocratic mobile phase consisting of water, 
acetonitrile, trifluoroacetic acid, and propionic acid (10:90:0.025:1 
by volume) with a chromatographic run time of 7 min, as reported 
previously (2, 19).
Statistical analyses
Data are presented as median with 95% confidence intervals (CIs). 
Differences between groups were analyzed by the non-parametric 
Mann-Whitney rank sum test (U test). Changes from baseline to the 
1-year and 2-year follow-up assessments were analyzed by means of 
the Friedman test. Correlation analyses were performed using the 
Spearman rank correlation coefficients (r, two-tailed) for explor-
ing associations between two variables. Analysis of covariance 
(ANCOVA) was used to determine associations between atorvas-
tatin, HoArg, and ADMA. Significant differences were assumed for 
p < 0.05. The statistical analyses were carried out with commercially 
available software (SPSS version 20.0; Chicago, IL, USA). In addition, 
post hoc power analyses were performed using the non-commercial 
G*Power 3.1.7 software for Windows (Heinrich Heine University, 
 Düsseldorf, Germany; www.psycho.uni-duesseldorf.de/abteilungen/
aap/gpower3).
Results
Basic characteristics of children with and without T1D are 
shown in Table 1. Regarding the sex distribution, there 
was no statistically significant difference between chil-
dren with and without T1D (p = 0.115). In children with 
T1D, urinary albumin level at the end of the follow-up 
period was 0.35 μmol/L (2.4 mg/dL) in patients receiv-
ing atorvastatin compared to 0.81 μmol/L (5.6 mg/dL) in 
placebo-treated patients (p = 0.50), based on the defined 
normal value  < 2.17 μmol/L (15 mg/dL). Serum creatinine 
was measured in children with T1D at baseline [atorvas-
tatin group = 63.65 μmol/L (0.72 mg/dL) versus placebo 
group = 58.35 μmol/L (0.66 mg/dL), p = 0.69] and at the end 
of the follow-up period [atorvastatin group = 70.72 μmol/L 
(0.80 mg/dL) versus placebo group = 69.84 μmol/L (0.79 
mg/dL), p = 1.00]. None of the enrolled children with T1D 
had a kidney disorder.
Post hoc analyses were performed for power calcula-
tion to detect differences of ADMA or HoArg between the 
two independent baseline groups (28 children with T1D 
versus 41 children without diabetes) at a significance level 
of α = 0.05. The power (1-β error probability) was 100% for 
ADMA and 94% for HoArg.
At baseline and prior to atorvastatin therapy, HoArg 
and ADMA were significantly lower in children with T1D 
compared to controls (Table 1). In T1D subjects, inverse 
correlations were found between HoArg and HbA1c 
(r = –0.677, p < 0.001) and between ADMA and HbA1c 
(r = –0.351, p = 0.085); systolic blood pressure (r = –0.548, 
p = 0.005); and pulse pressure (r = –0.577, p = 0.003). No 
significant correlations were found between further car-
diovascular risk factors (age, BMI-SDS, diabetes dura-
tion, LDL cholesterol, HDL cholesterol, triglycerides) and 
ADMA or HoArg.
The 2-year atorvastatin therapy did not have any sig-
nificant influence on plasma concentrations of HoArg 
and ADMA (Table 2). Analysis of covariance (ANCOVA) 
revealed no association between atorvastatin and HoArg 
(F = 3.060, p = 0.096) or ADMA (F = 0.073, p = 0.789).
Discussion
One of the earliest stages in the development of atheroscle-
rosis is endothelial cell dysfunction which is characterized 
by reduced bioavailability of NO formed from arginine 
through eNOS in the vascular endothelium (20). Relevant 
key factors for diabetes-related endothelial dysfunc-
tion are insulin deficiency and hyperglycemia (12). Most 
recently, there have been various publications indicating 
that decreased plasma concentrations of HoArg may play 
an important role as a cardiovascular risk marker (3, 5, 6). 
But the question whether and how HoArg is involved in 
diabetes-related endothelial dysfunction still needs to be 
answered. So far, it is known that HoArg can be involved 
in insulin release which in turn acts as an activator of 
eNOS to convert arginine into NO and citrulline (21). In 
our investigation, children and adolescents with T1D had 
significantly lower HoArg levels than healthy controls pos-
sibly suggesting their increased cardiovascular risk. Inter-
estingly, in another study with 40 healthy children and 
adolescents, the same median plasma homoarginine con-
centration was measured as in our controls. An association 
between intimamedia thickness or extramedial thickness 
of common carotid arteries and homoarginine could not be 
found (22). In general, children with T1D however are at 
high risk of premature, subclinical atherosclerosis which 
has been confirmed by providing evidence of endothe-
lial dysfunction and increased intimamedia thickness (7, 
23). One particularly interesting aspect of our study is the 
inverse correlation between HoArg and HbA1c in children 
with T1D which leads to the thought that there are close 
links between HoArg and glucose metabolism. Chronic 
hyperglycemia is one of numerous risk factors affecting 
endothelial function (24) and is very evidently accom-
panied by low HoArg plasma levels. Because it is a fact, 
that HoArg is an alternative substrate for eNOS, an animal 
study is instructive revealing improved NO bioavailability 
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Table 2 L-arginine, asymmetric dimethylarginine, and L-homoarginine in children with type 1 diabetes at baseline, 1 year, and 2 years after 
therapy with atorvastatin or placebo.
Parameter  
 
Atorvastatin (10 mg/day) 
 
Placebo
Baseline 
(n = 18)
  1 year 
(n = 16)
  2 years 
(n = 14)
  p-Valuea Baseline 
(n = 10)
  1 year 
(n = 9)
  2 years 
(n = 8)
  p-Valuea
Arginine, μmol/L   128.2  128.2  113.8  NS   133.1  153.1  158.0  NS
  (110.8–155.9)  (111.8–161.6)  (97.7–137.1)    (119.5–158.2)  (111.8–190.6)  (102.7–184.3) 
ADMA, nmol/L   422.1  422.5  407.0  NS   399.7  410.7  397.4  0.034
  (395.4–495.1)  (391.2–481.6)  (373.6–452.3)    (356.2–516.1)  (356.2–524.0)  (326.9–483.2) 
Homoarginine, μmol/L   1.000  0.900  0.900  NS   0.900  1.0  1.050  NS
  (0.893–1.121)  (0.852–1.085)  (0.797–1.017)    (0.852–1.104)  (0.867–1.133)  (0.860–1.240) 
LDL cholesterol, mg/dLb   85.0  63.5  54.5   < 0.01   85.0  75.0  84.0  NS
  (77.2–104.7)  (48.4–75.6)  (48.1–70.8)    (70.2–98.7)  (58.2–96.9)  (72.4–106.9) 
HbA1c, %   7.9  8.2  8.3  NS   8.2  7.8  8.7  NS
  (7.4–8.5)  (7.7–87)  (7.7–9.2)    (7.0–9.0)  (6.9–8.9)  (7.5–9.3) 
Data are medians (95% CI); aChanges from baseline to the 2-year assessments were analyzed by the Friedman test; ADMA, asymmetric 
dimethylarginine; LDL, low-density lipoprotein; NS, not significant. bTo convert values to mmol/L, multiply by a factor of 0.0259.
by supplying arginine in hyperglycemic diabetic mice (25). 
Further investigations are warranted with particular regard 
to the role of HoArg in insulin and glucose regulation, and 
the potential of HoArg to act as a cardiovascular risk factor 
or serve as a clinically relevant diagnostic marker.
The mode of action of the eNOS-inhibitor ADMA as 
a risk marker for endothelial dysfunction and cardiovas-
cular disease has been described in a large number of 
reports. In contrast to these investigations in non-diabetic 
adults where it was concluded that elevated ADMA levels 
are associated with subclinical atherosclerosis, cardiovas-
cular events, and even total mortality (9–11), the impor-
tance of elevated ADMA in adult diabetic patients is far 
less clear due to diverse relationships with the metabo-
lism of insulin and glucose, and diabetic vascular compli-
cations (12) Our particular aim was to determine clinical 
data, including long-term data regarding ADMA in chil-
dren with T1D and to review the current literature on these 
subjects. In a study conducted in children and adolescents 
with T1D, it was demonstrated that ADMA plasma concen-
tration was lower in diabetic than in healthy children, 
thereby probably activating atherogenic mechanisms by 
increased oxidative stress (13). We can also confirm from 
our own experience that ADMA concentration is signifi-
cantly lower in children with T1D compared to healthy 
controls. Interestingly, it has been demonstrated that in 
human cultured endothelial cells ADMA accumulation 
was dose-dependently inhibited by insulin via changes 
in the activity of dimethylarginine-dimethylaminohydro-
lase (26). Furthermore, it was shown that both in young 
men with borderline hypertension and in adolescents and 
young adults with T1D ADMA concentration decreased 
significantly as the result of short-term insulin infusion 
(27, 28). Insulin-mediated increased cellular absorption 
or decreased release of ADMA and the improvement of 
hyperglycemia-induced down-regulation of the ADMA-
degrading enzyme dimethylarginine-dimethylaminohy-
drolase by insulin have been discussed as main causes. 
In children with T1D, insulin absorption occurs indepen-
dently of the current blood glucose level from the insulin 
depot in the subcutaneous tissue causing therapeutic, 
exogenous hyperinsulinemia which may thus contribute 
to their low ADMA levels.
In our children with T1D, the lowered endothelial 
parameters HoArg and ADMA did not change signifi-
cantly in the course of the 2-year study. In placebo-treated 
patients, HoArg increased slightly and ADMA remained 
more or less at the same level. With regard to atorvas-
tatin, there are some initial indications in the literature 
showing potential reduction of arterial stiffness in chil-
dren with T1D (29). In the course of the effective atorv-
astatin treatment of our T1D patients, indicated by the 
significant reduction of LDL cholesterol, HoArg and 
ADMA showed only a small decrease. We think there-
fore that there is no simple causal relationship between 
these parameters, LDL cholesterol, and statin treatment. 
It is well known that statins also exert pleiotropic, lipid-
independent effects such as increasing the expression 
of eNOS or reducing oxidative stress (15, 30) that could 
lead to an improvement of endothelial function. While no 
published data on HoArg could be found, ADMA levels, 
just as with our study, showed no significant reduction 
during statin treatment in various clinical trials (14, 
30). However, a recent study in ischemic stroke patients 
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revealed a significant relation between statin treatment 
and decreased ADMA levels (15).
In conclusion, decreased plasma levels of HoArg and 
ADMA in T1D children and their correlation with gener-
ally accepted cardiovascular risk factors may suggest that 
the two parameters are possibly associated with early ath-
erosclerotic vascular changes. In the case of HoArg, there 
is an association with poor glycemic control that leads to 
hyperglycemia, whereas ADMA is correlated with systolic 
blood pressure, pulse pressure, and probably HbA1c. The 
2-year atorvastatin therapy did not have any significant 
influence on comparatively low plasma concentrations of 
HoArg and ADMA in children with T1D. However, future 
long-term studies with larger patient numbers are war-
ranted to confirm the role of HoArg and ADMA in T1D and 
atherosclerosis.
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